Ercan Müldür

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia

Heinz Ludwig, Ercan Müldür, Georg Endler et al. · Annals of Oncology · 2013 · 254 citations · Full text

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

Wolfgang Lamm, Wolfgang Willenbacher, Alois Lang et al. · Annals of Hematology · 2010 · 63 citations · Full text

Medicine, Systemic Al Amyloidosis, Pharmacology +1

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study

Heinz Ludwig, Elisabeth Rauch, Thomas Kuehr et al. · Haematologica · 2014 · 28 citations · Full text

Renal Pathology, Phase Ii Study, Dialysis Therapy +17

Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma

Johanna Gebhart, Klaus Lechner, Cathrin Skrabs et al. · Thrombosis Research · 2014 · 24 citations

Thrombosis, Lymphoid Neoplasia, Autoimmune Disease +7